Novo targets blockbuster-heavy 2030 but share slump signals unease
Shares in Novo have slumped despite the drugmaker outlining a five-year commercial strategy in a bid to return to winning…
22 Sep 2026
Made Scientific acquires cell therapy facility in Pennsylvania, US
Made Scientific has acquired an 85,000ft² cell therapy manufacturing facility in Pennsylvania, US, from National Resilience, adding an operational site to its US East Coast network. The company said programmes…
22 Sep 2026
EC approves Menarini and NewAmsterdam’s obicetrapib therapies
The European Commission (EC) has granted marketing authorisation to NewAmsterdam Pharma and Menarini Group for Ubeslo (obicetrapib 10mg monotherapy) and Evlarco (10mg obicetrapib plus 10mg ezetimibe fixed-dose combination). The authorisation…
21 Sep 2026
Beijing unveils blueprint for biomedical dominance by 2030
The Chinese government has unveiled an ambitious five-year plan for its biomedical industry, as the country looks to cement its role as a powerhouse in the global drug innovation landscape.…
21 Sep 2026
Telix to acquire ITM in deal worth up to $2.35bn
Australia-based Telix Pharmaceuticals has agreed to acquire ITM Isotope Technologies Munich in a transaction valued at up to $2.35bn. The deal combines Telix’s operations with ITM’s radioisotope production business and…
21 Sep 2026
Sandoz and mAbxience agree on emicizumab biosimilar partnership
Sandoz and mAbxience have signed a licensing, development, manufacturing and commercialisation agreement covering a proposed emicizumab biosimilar candidate for haemophilia A. The candidate is in early-stage development and references Hemlibra…
18 Sep 2026
FDA approves first gene therapy for Sanfilippo syndrome type A
The US Food and Drug Administration (FDA) has approved Ultragenyx’s gene therapy for Sanfilippo syndrome type A, marking the first treatment of its kind greenlit for children with the genetic…